Your browser is no longer supported. Please, upgrade your browser.
AGN Allergan plc daily Stock Chart
Allergan plc
IndexS&P 500 P/E- EPS (ttm)-3.12 Insider Own0.20% Shs Outstand356.40M Perf Week2.15%
Market Cap86.62B Forward P/E13.57 EPS next Y17.91 Insider Trans-8.22% Shs Float334.81M Perf Month1.05%
Income-1219.50M PEG- EPS next Q3.32 Inst Own93.00% Short Float3.37% Perf Quarter15.63%
Sales14.57B P/S5.95 EPS this Y63.30% Inst Trans0.03% Short Ratio3.86 Perf Half Y8.19%
Book/sh199.95 P/B1.22 EPS next Y11.71% ROA10.90% Target Price268.67 Perf Year10.76%
Cash/sh37.11 P/C6.55 EPS next 5Y13.90% ROE19.60% 52W Range183.98 - 260.53 Perf YTD16.06%
Dividend2.80 P/FCF106.48 EPS past 5Y-28.70% ROI0.10% 52W High-6.71% Beta1.16
Dividend %1.15% Quick Ratio2.20 Sales past 5Y26.00% Gross Margin87.20% 52W Low32.11% ATR2.94
Employees16700 Current Ratio2.30 Sales Q/Q7.10% Oper. Margin-12.50% RSI (14)61.28 Volatility1.10% 1.20%
OptionableYes Debt/Eq0.47 EPS Q/Q85.60% Profit Margin- Rel Volume0.75 Prev Close239.50
ShortableYes LT Debt/Eq0.42 EarningsMay 09 BMO Payout0.00% Avg Volume2.93M Price243.05
Recom2.00 SMA202.08% SMA501.10% SMA2006.49% Volume2,203,452 Change1.48%
Feb-09-17Reiterated Mizuho Buy $273 → $275
Dec-09-16Reiterated Credit Suisse Outperform $301 → $274
Nov-17-16Reiterated Mizuho Buy $293 → $273
Nov-03-16Reiterated RBC Capital Mkts Outperform $300 → $279
Nov-01-16Reiterated Mizuho Buy $299 → $293
Oct-31-16Resumed Barclays Equal Weight $250
Oct-11-16Reiterated Mizuho Buy $305 → $299
Aug-19-16Upgrade Mizuho Neutral → Buy $248 → $318
Aug-09-16Reiterated RBC Capital Mkts Outperform $307 → $300
Aug-09-16Reiterated Deutsche Bank Buy $282 → $278
Aug-05-16Reiterated Mizuho Neutral $232 → $246
Jul-27-16Reiterated Leerink Partners Outperform $272 → $294
Jul-25-16Initiated Credit Suisse Outperform $327
May-13-16Reiterated Mizuho Neutral $250 → $232
Apr-18-16Resumed Goldman Buy $275
Apr-18-16Initiated Guggenheim Neutral
Apr-18-16Downgrade Piper Jaffray Overweight → Neutral $311 → $238
Apr-07-16Resumed Morgan Stanley Overweight $300
Apr-07-16Resumed JP Morgan Overweight
Apr-07-16Reiterated UBS Buy $366 → $300
Apr-26-17 01:12PM  Teva Confirms CFO Is Leaving
Apr-25-17 05:58PM  PBF Energy Set to Join S&P MidCap 400; Apollo Commercial Real Estate Finance and Waddell & Reed Financial to Join S&P SmallCap 600 PR Newswire
04:47PM  Jerome Dodson Keeps Buying McKesson, Axalta, Pentair
01:39PM  Gilead Sciences: NASH BridgesTo What?
07:31AM  Allergan Granted Marketing Authorization by the FDA for TrueTear, the First Intranasal Neurostimulating Device Proven to Temporarily Increase Tear Production PR Newswire
Apr-24-17 01:52PM  NASH: The next untapped pharma market gives investors many options Reuters
01:10PM  Trump Executive Order Could Revive Allergan-Pfizer Merger
09:42AM  3 Healthcare Bargain Stocks You Can Buy Right Now Motley Fool
07:38AM  Novartiss 1Q17 Estimates for Sandoz Market Realist
07:00AM  NASH: The next untapped pharma market gives investors many options Reuters
01:00AM  NASH: The next untapped pharma market gives investors many options Reuters
Apr-23-17 11:41AM  Should Gilead Sciences Be Worried About Allergan? Motley Fool
Apr-21-17 03:28PM  Charlie Munger: Loading Up on Leverage
09:00AM  Top Analyst Upgrades and Downgrades: Costco, Dominos Pizza, Fortinet, Verizon, Yum Brands and More 24/7 Wall St.
07:12AM  Pharma Stock Roundup: J&J Slips on Mixed Q1, Lilly Hit by FDA CRL Zacks
Apr-20-17 04:15PM  Allergan Announces 13 Presentations on Chronic Migraine, Upper and Lower Limb Spasticity, Cervical Dystonia and Alzheimer's Disease at the American Academy of Neurology Meeting in Boston PR Newswire
02:15PM  Chapel Hill company partners with Allergan American City Business Journals
09:00AM  Allergan Partners with TARGET PharmaSolutions to Advance NASH Research PR Newswire
Apr-19-17 10:11AM  Allergan (AGN) Collaborates with Novartis to Treat NASH Zacks
07:00AM  [$$] Investors bet on Incyte drug success Financial Times
Apr-18-17 04:51PM  Allergan, Argentum settle patent dispute over eye drug Restasis Reuters
01:15AM  Allergan Expands Leading Research & Development NASH Program with Novartis Clinical Collaboration PR Newswire
Apr-17-17 06:33AM  A Healthcare Pick That's Moderately Shielded From Upheaval Morningstar
Apr-13-17 03:40PM  Why Charlie Munger Hates Value Investing
09:00AM  Allergan and Ironwood Launch Campaign Designed to Empower the Nearly 64 Million Americans Estimated to Suffer from IBS and CIC to Talk About Bowel Health(1-5) PR Newswire
Apr-12-17 06:03AM  The Real Trump Trade May Be Gold: Cramer's 'Mad Money' Recap (Tuesday 4/11/17)
Apr-11-17 07:12PM  Cramer Remix: Why a slew of IPOs might not be a good thin... CNBC Videos
06:53PM  Cramer's charts show these biotechs ignoring their 'polit... CNBC Videos
07:30AM  Allergan Launches Frames of Mind, Encouraging People Living with Migraine to Share Common Experiences Through Art PR Newswire
Apr-10-17 10:36AM  How Did Allergan Perform in 1Q17? Market Realist
09:00AM  Allergan Receives 2017 ENERGY STAR® Partner of the Year - Sustained Excellence Award from U.S. Environmental Protection Agency PR Newswire
01:00AM  Takeaways and Observations; Play a Tesla Tune: Doug Kass' Views
Apr-09-17 03:55PM  Valeant: It's Not a Game of Chess - Part IV
Apr-08-17 11:30AM  Allergan is still hopeful about using Botox to treat depression MarketWatch
Apr-07-17 11:00AM  Allergan Teams Up With Media Mogul Wendy Williams to Debut the Patient Empowerment Campaign - Toilet Talk PR Newswire
10:24AM  3 Stocks the Smartest Investors Are Buying Right Now Motley Fool
08:47AM  5 Drug Stocks for Your Portfolio this World Health Day Zacks
Apr-06-17 04:15PM  Allergan Names Daphne Karydas as Senior Vice President of Global Investor Relations & Strategy PR Newswire
01:35PM  Allergan Guilty of Wishful Botox Thinking Bloomberg
11:30AM  Allergan's Botox Studied as Depression Treatment Investopedia
11:29AM  [$$] Investors question Allergan move to test Botox for depression Financial Times
11:18AM  Allergan (AGN) Presents Mixed Depression Data on Botox Zacks
08:31AM  Allergan Plc breached its 50 day moving average in a Bearish Manner : AGN-US : April 6, 2017 Capital Cube
08:22AM  Novartis Licenses ECF843 Eye Drops From Lubris Investopedia
08:00AM  Allergan and ZELTIQ Announce Expiration of Hart-Scott-Rodino Waiting Period for Pending Transaction PR Newswire
Apr-05-17 05:30PM  Allergan to move Botox into late-stage testing for depression Reuters
04:30PM  Allergan Reports Topline Phase II Data Supporting Advancement of BOTOX® (onabotulinumtoxinA) for the Treatment of Major Depressive Disorder (MDD) PR Newswire
04:18PM  Allergan To Test Botox For Depression Despite Mixed Results Forbes
08:00AM  Allergan to Report First Quarter 2017 Earnings and Host Conference Call and Webcast PR Newswire
02:46AM  Why Is Allergan (AGN) Down 2.2% Since the Last Earnings Report? Zacks
Apr-04-17 12:20PM  Paratek shares soar as antibiotic passes late-stage hurdle American City Business Journals
11:14AM  Why Paratek Pharmaceuticals Inc Is Soaring Motley Fool
Mar-31-17 10:36AM  Exploring Eli Lillys Oncology Franchise in 2016
07:21AM  Pharma Stock Roundup: FDA Nod for SNY, Roche Drugs, Generic Advair Relief for GSK? Zacks
07:00AM  Healthcare: Stock-Picking Increasingly Important as Valuations Rise Morningstar
Mar-30-17 11:45AM  Why Equal Weighted Mutual Funds Scoring Over Index Funds Investopedia
07:27AM  Bill Ackman apologizes for $4 billion Valeant mistake (finally) at MarketWatch
Mar-29-17 06:25PM  Bill Ackman's Insider Trading Lawsuit May Cost Pershing Square Investors $75 Million
05:40PM  Fast Money Madness: Nvidia vs. Allergan
03:47PM  Here's the Bill Ackman apology Wall Street's been waiting for
07:00AM  Market Outlook: Lofty Valuations Call for Careful Stock-Picking at Morningstar
Mar-28-17 04:30PM  Did This Beauty Giant Just Solve The Acne Challenge?
04:09PM  2016s Top Earning Hedge Fund Managers And Their Favorite Stocks at Insider Monkey
11:47AM  Allergan Acne Candidate Meets Endpoints in Phase III Studies
08:15AM  Blog Coverage Allergan and Paratek's Acne Drug Reported Positive Results Accesswire
Mar-27-17 07:00PM  Risk-Reward With Teva Pharmaceutical
06:00PM  Why Impax Labs Soared 37.3% Today at Motley Fool
05:46PM  Health care showdown: Allergan vs. Valeant
05:05PM  DuPont, Impax Labs gain, G-III Apparel slides
01:20PM  Has Allergan's Pullback Ended?
12:41PM  Why Moat Indexes Outperformed Others in February
11:34AM  Allergan, Parateks Acne Drug Succeeds in Phase 3 at Investopedia
11:20AM  Paratek eyes FDA filing as acne drug clears late-stage trials at
11:20AM  Foamix Acne Drug Fails Late-Stage Study at Investopedia
09:28AM  Skincare Makers Lead Biotech Movers
07:48AM  Allergan, Paratek Pharma report positive results in late-stage trial of acne treatment at MarketWatch
07:36AM  Vyzulta May Be a Potent Therapy for Glaucoma in the Future
07:31AM  Allergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate to Severe Acne PR Newswire
07:30AM  Allergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate to Severe Acne GlobeNewswire
Mar-26-17 11:01AM  3 Great Stocks to Buy in a Market Pullback at Motley Fool
Mar-24-17 02:00PM  Can Anyone Challenge Allergan In Medical-Aesthetics Market?
07:35AM  Valeant Pharmaceuticals is Developing its Sales Force
01:00AM  After Trump rally, equity investors move into healthcare, retailers Reuters
Mar-23-17 06:31PM  The Most Attractive Value Stock There Is?
11:24AM  Insys Therapeutics' Syndros Gets Final DEA Rule at Investopedia
10:19AM  Allergan's Restasis Now Available in Multidose Bottle in U.S.
09:20AM  Buyback ETF Steady As Repurchases Decline
09:06AM  Teva Denies Reports About 11% Global Workforce Reduction (TEVA) at Investopedia
08:59AM  The Supreme Court could fundamentally change America's broken patent system
Mar-22-17 06:45PM  Companies Spend Less on Share Buybacks for Second Year in 2016
04:35PM  Allergan, Dow's Apple Lead Q4 Buybacks; Health Care Atop S&P 500
02:52PM  Allergan Stock Reacts Well In Downtrodden Sector at Investopedia
10:30AM  Latest Editas research pact could be worth up to $1 billion at
07:31AM  Allergan Announces Availability of RESTASIS MULTIDOSE (Cyclosporine Ophthalmic Emulsion) 0.05% -- the First FDA-Approved Preservative Free Prescription Eye Drop Available in a Multidose Bottle PR Newswire
Mar-21-17 05:35PM  David Tepper Takes Big Risks for Big Rewards
05:26PM  FDA Links Breast Implants To A Rare Form Of Cancer
02:58PM  Allergan's Dermal Filler for Wrinkle Correction Gets FDA Nod
Mar-20-17 04:51PM  Editas Get A Vetr Upgrade To Strong Buy
01:53PM  Allergan Is Setting Up Nicely for a Possible Move at Investopedia
07:31AM  JUVÉDERM VOLLURE XC Approved by U.S. FDA for Correction of Facial Wrinkles and Folds in Adults over the Age of 21 PR Newswire
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, the company distributes generic and branded pharmaceutical products primarily to independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics, and physician offices. Further, it develops a portfolio of breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. The company has licensing agreement with Assembly Biosciences, Inc.; Mimetogen Pharmaceuticals, Inc.; Almirall, S.A; Naurex, Inc.; and Merck & Co. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BISARO PAULDirectorMar 02Sale246.6870,00017,267,561235,900Mar 06 06:59 AM
Meury WilliamChief Commercial OfficerDec 08Option Exercise109.1211,8071,288,38048,866Feb 14 09:13 PM
Basgoz NesliDirectorDec 08Sale188.7250094,3605,515Dec 09 05:56 PM
SAUNDERS BRENT LCEO and PresidentNov 21Buy189.135,250992,941106,564Nov 21 04:03 PM
Hilado Maria TeresaChief Financial OfficerNov 11Buy210.641,422299,53613,379Nov 15 05:18 PM